Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Editorial

Waging war against rotavirus at home and abroad

Noni E. MacDonald, Daniel Rosenfield, Ken Flegel and Matthew B. Stanbrook
CMAJ June 12, 2012 184 (9) 1011; DOI: https://doi.org/10.1503/cmaj.120245
Noni E. MacDonald
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: noni.macdonald@dal.ca
Daniel Rosenfield
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken Flegel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew B. Stanbrook
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

Rotavirus is the most common cause of severe diarrhea in infants and young children worldwide. Recent studies have provided strong evidence that rotavirus vaccines are safe and efficacious in both the developed and the developing world.1–3 Although Canada has shown leadership in making this life-saving vaccine available to the poorest countries, it could do much more to help children both at home and abroad.

The gastroenteritis caused by rotavirus infection often results in severe dehydration requiring admission to hospital and, if not adequately treated, can result in electrolyte disturbances, shock and death. The mortality burden (more than 450 000 deaths per year3) is squarely focused on the developing world. Rotavirus is extremely contagious, which likely explains why increased hygiene alone has not reduced infections globally. Infants are disproportionately affected because of waning maternal antibodies and immature immune systems, but infections in infancy tend to confer lifelong immunity to future severe infections.

A rhesus rotavirus reassortant vaccine developed in the mid-1990s, although clinically effective, was removed from the market because of an increased risk for intussusception.4 Fortunately, two newer vaccines are available — RotaTeq (Merck) and Rotarix (GlaxoSmithKline) — that have shown safety and efficacy in reducing the incidence of severe diarrhea, decreasing hospital admissions for rotavirus in industrialized countries and deaths in developing countries.1,2

In contrast to universal coverage in the United States, the vaccine is publicly covered in Canada by four provinces — British Columbia, Ontario, Quebec and Prince Edward Island — and only privately available in the rest.5 Both the Canadian Paediatric Society and the National Advisory Committee on Immunization have called for it to be added to the routine infant vaccine schedule across the country. For Canada, this would result in bulk-buying discounts from suppliers, equity of access and broader herd protection, a phenomenon observed in the US.6

Rotavirus vaccine so unequivocally reduces morbidity and mortality in a cost-effective manner that the World Health Organization (WHO) has called for global adoption of the rotavirus vaccine. The Global Alliance for Vaccines and Immunisation (GAVI) has been at the forefront of supporting the rollout of the rotavirus vaccination campaign for the world’s poorest countries. Canada is a strong supporter, having met all its funding goals for GAVI to date. However, continued support for GAVI will be especially important as the vaccine is introduced across Africa over the next five years.

Although vaccination in many developing countries will largely depend on GAVI, thousands of children will continue to die in countries that do not qualify for GAVI funding to support purchase of vaccines. Specifically, countries with emerging economies such as India, China, Pakistan and Bangladesh do not have universal rotavirus vaccination programs, despite ample research indicating efficacy and cost-effectiveness, as shown in a recent study in India.7 The opportunity to start such a program is particularly salient for India, where Bharat Biotech currently has an indigenously developed rotavirus vaccine in phase III trials and soon plans to manufacture it for export.8

Canada should encourage and support developing nations to heed the WHO’s call for global rotavirus vaccination. Yet it is hard for us to advocate credibly to others for what we are failing to adopt ourselves. Canada has shown leadership on global health and vaccination efforts worldwide, as evidenced at the G8 summit in 2010 when we dedicated increased funding for GAVI. But to be true role models, our provincial and federal policy-makers must ensure that all Canadian infants are offered vaccination against rotavirus. Simultaneously, Canada should ensure the ongoing sustainability of GAVI by guaranteeing our funding despite current economic conditions and by encouraging other developed countries to do the same.

Footnotes

  • Competing interests: Noni MacDonald is a board member of the Canadian Paediatric Society (CPS), has received consulting fees from the World Health Organization (WHO), has grants or grants pending from the Canadian Institutes of Health Research and the International Development Research Centre, and has received travel accomodation for meetings from CPS, WHO and the Royal College of Physicians and Surgeons of Canada. None declared by Daniel Rosenfield. See www.cmaj.ca/site/misc/cmaj_staff.xhtml for Ken Flegel and Matthew Stanbrook.

References

  1. ↵
    1. Cortes JE,
    2. Curns AT,
    3. Tate JE,
    4. et al
    . Rotavirus vaccine and health care utilization for diarrhea in U.S. children. N Engl J Med 2011;365:1108–17.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Madhi SA,
    2. Cunliffe NA,
    3. Steele D,
    4. et al
    . Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010;362:289–98.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Tate JE,
    2. Patel MM,
    3. Cortese MM,
    4. et al
    . Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality. Expert Rev Vaccines 2012;11:211–20.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Bines J
    . Intussusception and rotavirus vaccines. Vaccine 2006;24:3772–6.
    OpenUrlCrossRefPubMed
  5. ↵
    Publicly funded immunization programs in Canada — routine schedule for infants and children including special programs and catch-up programs (as of December 2011). Ottawa (ON): Public Health Agency of Canada; 2011. Available: www.phac-aspc.gc.ca/im/ptimprog-progimpt/table-1-eng.php (accessed 2012 Jan. 25).
  6. ↵
    1. Lopman BA,
    2. Curns AT,
    3. Yen C,
    4. et al
    . Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011;204:980–6.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Esposito DH,
    2. Tate JE,
    3. Kang G,
    4. et al
    . Projected impact and cost-effectiveness of a rotavirus vaccination program in India. Clin Infect Dis 2011;52:171–7.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Bharat Biotech announces the price of Rotavac, its potential vaccine against rotavirus diarrhoea. Hyderabad (India): Bharat Biotech; 2011. Available: www.bharatbiotech.com/BBIL-GAVI-ROTAVAC-Press%20Release-06June2011-F.pdf (accessed 2012 Feb. 21).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 184 (9)
CMAJ
Vol. 184, Issue 9
12 Jun 2012
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Waging war against rotavirus at home and abroad
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Waging war against rotavirus at home and abroad
Noni E. MacDonald, Daniel Rosenfield, Ken Flegel, Matthew B. Stanbrook
CMAJ Jun 2012, 184 (9) 1011; DOI: 10.1503/cmaj.120245

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Waging war against rotavirus at home and abroad
Noni E. MacDonald, Daniel Rosenfield, Ken Flegel, Matthew B. Stanbrook
CMAJ Jun 2012, 184 (9) 1011; DOI: 10.1503/cmaj.120245
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Regard sur la santé des personnes noires et le racisme anti-Noirs dans les systèmes de santé au Canada
  • A focus on access to health care in Canada
  • L’avenir de la médecine est ici et vous en êtes la trame narrative
Show more Éditorial

Similar Articles

Collections

  • Topics
    • Global health
    • Infectious diseases
    • Vaccination

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire